Heidi Splete

Washington, D.C.

Journalist, Writer and Editor at Freelance

medical journalist, fitness enthusiast; managing editor, Skin & Allergy News

Featured in: Favicon

webmd.com

medscape.com (+3) Favicon

mdedge.com Favicon

practicalpainmanagement.com Favicon

khq.com

sentinelsource.com Favicon

nbcrightnow.com Favicon

appeal-democrat.com Favicon

fltimes.com Favicon

gillettenewsrecord.com + 37 more

Articles

Beneficio en el embarazo del uso de dosis bajas de ácido acetilsalicílico

1 week ago | espanol.medscape.com | Heidi Splete

El cambio del protocolo de prescripción de ácido acetilsalicílico en dosis bajas para la prevención de la preeclampsia desde una recomendación basada en el riesgo hasta una recomendación universal aumentó significativamente el uso de ácido acetilsalicílico en pacientes embarazadas, según los nuevos datos presentados en el Congreso Anual del American College of Obstetricians and Gynecologists (ACOG) de 2025.
Newly Approved Mepolizumab Mitigates COPD Exacerbations

1 week ago | medscape.com | Heidi Splete

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the MATINEE study presented at the American Thoracic Society (ATS) 2025 International Conference. Based on these findings, mepolizumab is newly approved by the US Food and Drug Administration for the treatment of COPD according to manufacturer GlaxoSmithKline.
Prenatal Exposure, Maternal Factors Drive Childhood BMI

1 week ago | medscape.com | Heidi Splete

Maternal factors, including high maternal prepregnancy body mass index (BMI), high weight gain during pregnancy, and smoking, were associated with an atypically high BMI trajectory in children, based on data from nearly 9500 children.
Vacinação contra vírus sincicial respiratório é associada a menos hospitalizações infantis

1 week ago | portugues.medscape.com | Heidi Splete

As taxas de hospitalização associadas ao vírus sincicial respiratório (VSR) entre bebês nos Estados Unidos foram significativamente menores no primeiro ano em que os produtos de prevenção estiveram amplamente disponíveis, segundo dados da rede de vigilância referentes ao período de 2024–2025. Durante essa temporada, foram utilizados tanto a vacina materna contra o VSR quanto o anticorpo monoclonal de ação prolongada nirsevimabe para bebês e crianças pequenas de 0 a 19 meses, escreveram a Dra.
Agências aconselham suspensão do uso da vacina contra chikungunya em adultos com 60 anos ou mais

1 week ago | portugues.medscape.com | Heidi Splete

Os profissionais de saúde devem suspender a administração da vacina viva contra chikungunya (Ixchiq) enquanto prossegue a avaliação de eventos adversos graves (neurológicos, cardíacos e outros) em pessoas vacinadas, segundo comunicado de segurança emitido em conjunto pela Food and Drug Administration (FDA) e os Centers for Disease Control and Prevention (CDC) dos Estados Unidos. Até 7 de maio de 2025, foram registrados 17 eventos adversos graves, incluindo dois óbitos.
New Criteria Pin Down Difficult-to-Manage Axial Spondyloarthritis

2 weeks ago | medcentral.com | Heidi Splete

A substantial number of patients with axial spondyloarthritis (axSpA) do not achieve remission or respond to treatment despite available therapies, but a new definition offers guidance to improve clinical care.
FDA Approves Roflumilast Foam for Scalp, Body Psoriasis

2 weeks ago | medscape.com | Heidi Splete

The foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast has been approved by the US Food and Drug Administration (FDA) for treating plaque psoriasis of the scalp and body in adults and adolescents aged 12 years and older, according to an announcement from the manufacturer Arcutis Biotherapeutics. The 0.3% foam formulation of roflumilast (Zoryve) was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.
BLVR Requires Revision in 20% of Patients

2 weeks ago | medscape.com | Heidi Splete

Approximately 20% of patients who undergo bronchoscopic lung volume reduction (BLVR) lose the effects of the treatment within 2 years, according to data presented at the American Thoracic Society (ATS) 2025 International Conference in San Francisco. Although BLVR has become common, data on the need and reasons for revision are limited, wrote Jiji Thomas, MBBS, Manager of Special Procedures at the Temple Lung Center, Philadelphia, and colleagues in their abstract.
Quick Turn to Mechanical Thrombectomy Improves PE Outcomes

2 weeks ago | medscape.com | Heidi Splete

Patients with pulmonary embolism (PE) who were treated with mechanical thrombectomy (MT) within 12 hours of hospital admission had significantly better pulmonary outcomes than patients treated with mechanical thrombectomy more than 12 hours after admission, based on new data from the FLASH registry.
Can you identify a potential thyroid emergency?

2 weeks ago | medcentral.com | Heidi Splete

Thyroid storm is a life-threatening, emergent condition that develops from untreated or undertreated hyperthyroidism or overactive thyroid (thyrotoxicosis). A diagnosis of thyroid storm needs clinical suspicion, and clinicians should not wait for results of lab tests before starting treatment, wrote Binod Pokhrel, MD, of the University of Health Sciences, Lahore, Pakistan, and colleagues in a summary of thyroid storm in StatPearls.